Injectable monophase hydrogels

Abstract

An injectable monophase hydrogel is provided that is made of a reaction mixture of hyaluronic acids having different molecular weights.

What is claimed is: 
     
         1 . An injectable polymeric composition comprising a homogenized crosslinked mixture, wherein the mixture comprises a first hyaluronic acid salt having an intrinsic viscosity of 600 ml/g crosslinked with a second hyaluronic acid salt having an intrinsic viscosity of 2800 ml/g. 
     
     
         2 . The composition of  claim 1 , wherein hyaluronic acid is present at a concentration of between 10 and 40 mg/g. 
     
     
         3 . The composition of  claim 1 , wherein hyaluronic acid is present at a concentration of between 20 and 30 mg/g. 
     
     
         4 . The composition of  claim 1 , wherein hyaluronic acid is present at a concentration of 26 mg/g. 
     
     
         5 . The composition of  claim 1 , wherein the composition has an injection force of 14 N through a 27 G ½ needle/100 N dynamometer. 
     
     
         6 . The composition of  claim 1 , prepared by a process comprising the steps of:
 mixing the first hyaluronic acid salt and the second hyaluronic acid salt;   cross-linking the mixture; and   homogenizing the crosslinked mixture to obtain the injectable composition.   
     
     
         7 . The composition of  claim 6 , wherein the weight ratio of the first hyaluronic acid salt to the second hyaluronic acid salt is 90:10. 
     
     
         8 . The composition of  claim 6 , wherein the cross-linking is performed in an aqueous solvent. 
     
     
         9 . The composition of  claim 6 , wherein the cross-linking is performed in the presence of an effective and non-excessive amount of at least one cross-linking agent. 
     
     
         10 . The composition of  claim 9 , wherein the cross-linking agent is 1,4-butanediol diglycidyl ether (BDDE). 
     
     
         11 . The composition of  claim 6 , wherein the weight ratio of the first hyaluronic acid salt to the second hyaluronic acid is 90:10, and
 wherein the cross-linking is performed in an aqueous solvent in the presence of an effective and non-excessive amount of at least one cross-linking agent.